SHELTON, CT / ACCESSWIRE / September 2, 2020 / NanoViricides, Inc. (NYSE:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 8:20 AM PDT / 11:20 AM EDT. Anil R. Diwan, PhD, President and Executive Chairman of the Company, will be presenting to a live audience.
NanoViricides has successfully performed significant drug development work against COVID-19 and believes it is close to declaring a clinical candidate. Our current COVID-19 drug development candidates have shown efficacy against multiple different coronaviruses in our BSL2 virology lab. The Company believes this research provides scientific support that the virus would not be able to escape our drug candidate despite mutations, unlike many other drugs, antibodies and vaccines.
In addition, our current development candidates against COVID-19 have also been shown to be extremely safe in animal studies. Their effectiveness in cell culture and animal models has led us to believe that they are worthy of human clinical development.
Subsequently, the Company has completed CMC ("Chemistry, Manufacture, and Controls") studies that would be required for an IND ("Investigational New Drug) application to the U.S. FDA. The Company is also in the process of drafting sections of an IND for COVID-19 drug candidate. The Company is currently conducting studies to finalize its clinical candidate.
The Company develops its class of drugs, that we call nanoviricides®, using a platform technology. This approach enables rapid development of new drugs against a number of different viruses. A nanoviricide is a "biomimetic" - it is designed to "look like" the cell surface to the virus. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
Because of the worldwide urgency of the pandemic caused by the SARS-CoV-2 virus, we have focused all our efforts recently on taking a drug against SARS-CoV-2 into human clinical trials for treatment of patients with COVID-19. An effective drug could potentially allow full-fledged opening of normal activities, including schools, businesses, and economies all over the world.
Soon after it files an IND for a COVID-19 drug candidate, the Company intends to re-engage its NV-HHV-101 shingles drug candidate clinical trials program towards IND filing. The Company has put the shingles program on hold due to perceived difficulties in conducting proposed shingles clinical trials during the COVID-19 pandemic. The Company is near finalizing the selection of clinical trial sites and finalizing clinical trial protocols for the shingles IND filing.
The NV-HHV-101 drug candidate is expected to open up a billion dollar market forthe shingles treatment space, and also lead to further development of drugs against other herpesviruses such as HSV-1 that causes "cold sores" and HSV-2 that causes genital herpes. The multiple indications enabled by the HerpeCide™ program drug candidates may potentially address a several billion dollar marketspace.
For additional information about NanoViricides, please visit the company's website at www.nanoviricides.com .
The LD 500 On-line Conference will take place on September 1st through the 4th. To attend the Conference, please register at the link:
"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.
View NanoViricides' profile here: http://www.ldmicro.com/profile/NNVC